Now I have all the information I need. Let me compile the final review.

## Summary

This paper presents MUBen, a benchmark systematically evaluating 8 uncertainty quantification (UQ) methods across 4 primary pre-trained molecular backbone models (ChemBERTa, GROVER, Uni-Mol, DNN) on 14 MoleculeNet datasets. The benchmark covers both classification and regression tasks, uses scaffold splitting for OOD evaluation, and produces rankings and insights about which UQ methods work best with which backbones. Key findings include that Deep Ensembles consistently improve performance, larger models like Uni-Mol are more overconfident, and Bayesian methods BBP/SGLD are better suited for regression uncertainty.

## Strengths

- **Most comprehensive UQ benchmark for pre-trained molecular backbones to date.** The paper evaluates 8 UQ methods across 4 primary backbones (plus 2 secondary) on 14 datasets, far exceeding prior work that typically examined 1–3 methods. This systematic coverage fills a genuine gap — prior UQ studies in molecular property prediction largely predated or ignored recent pre-trained backbones like Uni-Mol.

- **Actionable, empirically grounded insights.** The paper provides specific findings that challenge naive assumptions: (i) larger models (Uni-Mol) are *more* overconfident and need more careful UQ selection; (ii) Bayesian methods BBP and SGLD improve regression calibration but hurt prediction accuracy on smaller backbones; (iii) pre-trained models do not always outperform hand-crafted RDKit features when combined with UQ. These are supported by rank-based evidence in the tables.

- **Deliberate OOD methodology and distribution-shift analysis.** The benchmark uses scaffold splitting (the standard OOD evaluation in molecular property prediction) and provides a dedicated analysis showing that RMSE increases nearly linearly with decreasing test–train Tanimoto similarity while calibration error stays stable (Figure 5.5). This directly supports the claim that UQ methods help distinguish predictions under distribution shift.

- **Ablation studies beyond standard reporting.** The inclusion of frozen-backbone vs. fine-tuned comparisons and random vs. scaffold splits (Table 3) provides mechanistic insight into overconfidence — e.g., frozen backbones yield better regression calibration because they are less prone to overfitting.

## Weaknesses

### Fatal
None.

### Major

- **Insufficient statistical rigor for the central claims.** All results are macro-averaged ranks across datasets computed from only 3 random seeds, with no confidence intervals, error bars, or significance tests. The paper's headline findings — "Deep Ensembles consistently enhance performance," "BBP and SGLD appear more suitable for regression" — are presented as prescriptive recommendations, but without quantifying variability the reader cannot distinguish genuine trends from noise. Three seeds are insufficient to reliably estimate rank distributions across heterogeneous datasets. This is the single most important limitation and weakens the benchmark's ability to support its main conclusions. (Section 5, Section 6)

### Minor

- **Coarse hyperparameter tuning acknowledged but its impact unquantified.** The paper explicitly states (Section 6) that "coarse-grained hyperparameter grids" were used. For methods like BBP, SGLD, and Focal Loss, whose performance is highly sensitive to hyperparameters, coarse grids can systematically disadvantage them. The paper notes this limitation, which is commendable transparency, but does not analyze whether the reported rankings would shift with deeper tuning. This limits the reliability of method-by-method recommendations.

- **No reporting of computational cost.** The paper notes Deep Ensembles have "substantial computational cost" but provides no quantitative comparison (training time, inference cost, parameter counts) across UQ methods. This is directly relevant to practitioners making selections.

- **Variance aggregation for multi-forward-pass methods is underspecified.** For MC Dropout and Deep Ensembles in regression, the paper should specify exactly how multiple forward passes are aggregated into a single predictive variance. The current description is vague and affects reproducibility.

### Trivial

- The paper refers to "OOD" for scaffold splits throughout, which is standard in the field, but a brief clarification that this is within-dataset covariate shift (not cross-dataset OOD) would strengthen precision.

- "3 individual training-test runs with random seeds 0, 1, and 2" — fixing seeds a priori is fine but 3 is a small number even by MoleculeNet standards.

## Nice-to-Haves

- A cross-dataset OOD evaluation (e.g., training on one dataset and testing on a different chemical distribution) would strengthen the claim that UQ methods detect distribution shift, though this is beyond the paper's stated scope.
- A hyperparameter sensitivity analysis for the most sensitive UQ methods (BBP, SGLD, Focal Loss) on a representative subset would address concerns about ranking robustness.

## Removed Points

- **"Lack of a true OOD evaluation set" (from harsh critic):** Removed because scaffold splitting is the standard OOD evaluation in molecular property prediction (used by GROVER, Uni-Mol, and other works the paper cites). The paper's OOD claims are consistent with community norms. The critic's demand for cross-dataset OOD is scope creep and not standard practice. This is moved to Nice-to-Haves.

- **Strength Finder claim about "Deliberate OOD evaluation via scaffold splitting and distribution-shift analysis":** Kept but downgraded from a core strength — scaffold splitting is standard practice, not an innovation of this paper. However, the dedicated distribution-shift analysis (Figure 5.5) is a genuine strength.

## Novel Insights

None beyond the paper's own contributions. The core insight — that even in this specific review process, the most impactful criticism (lack of statistical rigor) mirrors a concern that also appeared in the human review of DrugFlow (reviewer 3, weakness: "Complete disregard for statistical variation… This variation is not accounted for in any of the Tables") — suggests a broader pattern in this subfield where benchmarking papers invest heavily in coverage but underinvest in establishing whether observed differences are reliable. This is a methodological blind spot worth noting for the community.

## Suggestions

1. **Quantify uncertainty in the rankings.** At minimum, report standard deviations of ranks across seeds. Better yet, use bootstrapping over datasets to produce confidence intervals for rank averages. This directly addresses the main weakness.
2. **Report computational cost** (training time, inference time, parameter count) for each UQ method in a dedicated table.
3. **Clarify variance aggregation** for MC Dropout and Deep Ensembles in the regression setting — specify whether variances are averaged, stacked, or combined via law of total variance.
4. **Add a per-dataset significance test** (e.g., paired bootstrap or Wilcoxon) between the deterministic baseline and each UQ method on key metrics (NLL, ECE) for at least the primary backbones. This would establish which improvements are reliable.

## Score and Decision

**Anchors used for calibration:**

| Path | Avg Score | Comparison to MUBen |
|------|-----------|---------------------|
| `/home/wg25r/split_review/datasets/deepreview_13k_calibration/g3VCIM94ke.md` (DrugFlow) | 6.67 (Accept) | Methods paper with novel model contributions + modest UQ component. Stronger technical novelty. |
| `/home/wg25r/split_review/datasets/deepreview_13k_calibration/NSDszJ2uIV.md` (MARCEL) | 6.33 (Accept) | Novel benchmark with new datasets. Stronger novelty and execution. MUBen is slightly weaker due to no new data and weaker stats. |
| `/home/wg25r/split_review/datasets/deepreview_13k_calibration/NvJxTjTQtq.md` (EGraFFBench) | 6.00 (Reject) | Benchmark with serious soundness issues (models not reproducing). MUBen has no equivalent red flag, making it somewhat stronger. |
| `/home/wg25r/split_review/datasets/deepreview_13k_calibration/8jKuUHsndT.md` (Syntheseus) | 5.50 (Reject) | Benchmark library for retrosynthesis. Similar contribution type, similar limitations. MUBen is comparable. |
| `/home/wg25r/split_review/datasets/deepreview_13k_calibration/1JgWwOW3EN.md` (BenchMol) | 4.80 (Reject) | Multi-modality benchmark with mixed reviews (10,1,5,3,5). MUBen is more focused and better executed. |
| `/home/wg25r/split_review/datasets/deepreview_13k_calibration/R8YCBH5HWo.md` (MoleVers) | 4.50 (Reject) | Pre-training method with benchmarking component. MUBen is slightly stronger. |
| `/home/wg25r/split_review/datasets/deepreview_13k_calibration/u8L1zzGXRq.md` (Drug Response) | 3.00 (Reject) | Weak empirical study with unclear contributions. MUBen is substantially stronger. |

The paper addresses a timely and well-motivated problem with comprehensive experimental coverage. The core weakness is insufficient statistical rigor (3 seeds, no CI) for the prescriptive recommendations it advances. Relative to the anchors, the work sits between BenchMol (4.80, less focused) and Syntheseus (5.50, similar contribution type). It is weaker than the accepted MARCEL benchmark (6.33) due to lesser novelty and weaker statistical support. The contribution is real but the evidence is not fully reliable in its current form.

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>